1 month Post-Doublet Therapy (Firmago... - Advanced Prostate...

Advanced Prostate Cancer

22,286 members27,986 posts

1 month Post-Doublet Therapy (Firmagon & Nubeqa) PSA down from 335 to 32 and Testosterone down to 13

Rcole727 profile image
15 Replies

After approx. month of Doublet therapy with Firmagon & Nubeqa PSA (Oct 2024)down from last test in August 2024 335 to 32 and T down to 13. When I started I was ADT naive.

SE: some tolerable night hot flashes, some insomnia that was prescribed Seroquell which zonked me out the next day but helped a bit.

Generally when is it appropriate time wise for a follow up PET or bone scan to see how bone and lymph node mets are fairing?

Much thanks.

Written by
Rcole727 profile image
Rcole727
To view profiles and participate in discussions please or .
Read more about...
15 Replies
Tall_Allen profile image
Tall_Allen

You should do a PET scan when PSA rises to see if it is time to change your therapy.

PELHA profile image
PELHA in reply toTall_Allen

What about annual PET scans to monitor Mets even with PSA in decline?

Tall_Allen profile image
Tall_Allen in reply toPELHA

A test should only be done if a treatment change is possible.

PELHA profile image
PELHA in reply toTall_Allen

So if PSA decreasing assume improvement? Mets will not proliferate in this case?

Tall_Allen profile image
Tall_Allen in reply toPELHA

If PSA is decreasing, and you have no reason to suspect a low-PSA subtype, there is no reason to change therapy. Metastases are always proliferating, sometimes less, sometimes more, usually invisibly.

PELHA profile image
PELHA in reply toTall_Allen

His PSA has never been above 10 but has the bone mets. Confused how some have PSA in the hundreds but similar issue with cancer spread. So when you say low-PSA subtype could this be the case here and what does that mean? Thanks!! Trying to keep up with all this info!!

Tall_Allen profile image
Tall_Allen in reply toPELHA

It could be. If so, metastases may also not express PSMA either. I suggest an FDG PET/CT to be safe.

PELHA profile image
PELHA in reply toTall_Allen

Thanks! Will ask about this at Mayo appointment next month. He did have both gene and genome testing and nothing there.

Tall_Allen profile image
Tall_Allen in reply toPELHA

Histology and IHC of tumor tissue is more revealing than genomic testing for that.

gsun profile image
gsun

Why not triplet therapy?

Rcole727 profile image
Rcole727 in reply togsun

Recent study (9/2024) I believe available on this site that came to conclusion that Nubeqa and ADT Therapyl (Firmagon for me) as effective for mHSPC low/high volume as Triplet therapy.

Article: "Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensative Prostate Cancer from the Phase III ARANOTE trial. Fred Saad, et. al.

" Thus, the ARANOTE and ARASENS trials demonstrate efficacy benefits with darolutamide plus ADT with and without docetaxel for patients with mHSPC."

Thats my interpretation, anyhow. Ive provide this Global Phase 3 trial to my MO and urologist.

gsun profile image
gsun in reply toRcole727

The ARASENS trial was ADT plus chemo vs ADT plus Nubeqa plus chemo. The ARANOTE trial was darolumide plus ADT vs ADT plus chemo. Not the same as doublet vs triplet.

Rcole727 profile image
Rcole727 in reply togsun

I believethe trial /article in September 2024 was results of ADT and Nubeqa with no docetaxel...

gsun profile image
gsun

This was June/24.

The addition of darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and docetaxel led to improved overall survival (OS) and prolonged the time to metastatic castration-resistant prostate cancer (mCRPC) vs placebo plus ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to post-hoc findings from the phase 3 ARASENS trial

From the ARANOTE trial Sept./24 article:

Purpose: For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also for patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel improved OS versus ADT and docetaxel in patients with mHSPC. The ARANOTE trial evaluated darolutamide and ADT without chemotherapy in patients with mHSPC.

Sept./24

The ARANOTE trial included a total of 669 patients randomly assigned 2:1 to receive either darolutamide plus ADT (446 patients) or ADT alone (223 patients). Fred Saad, MD, of the Montreal Cancer Research Institute and the University of Montreal, was the study’s lead investigator, and he said that although ADT monotherapy is no longer considered a standard of care, at the time of ARANOTE’s design and still today, it is used alone in “a significant proportion of patients.”

there is no info on chemo added to this, so it’s not comparable.

NanoMRI profile image
NanoMRI

Appropriate times for me are to affirm, with multiple imaging methods and liquid blood biopsy testing, that current strategy is correct. I see no reason to wait and give this beast time and obscurity.

Not what you're looking for?

You may also like...

Dad’s blood reports. PSA and testosterone down but ALP up

Did some blood tests for day today The last blood tests were done on 2nd May - PSA 18 Alk Phos...
Tinkudi profile image

Stage 4 +4 PSA down from 370 to 0.08

I have stage 4 +4 Gleeson Psa which got out of the prostrate into the blood stream into some of...
Brianne07 profile image

Urologist Wants to switch from Firmagon & Nubeqa to Lupron with Nubeqa

The urologist started with first injection of Firmagon with Nubeqa and before the end of 28 days...
Rcole727 profile image

PSA down from 6.17 to 4.4 in 16 months

My friend was diagnosed with prostate cancer in December 2020. He was given the option of being on...

CV and Bone Health when ADT is a treatment option.

Thought this provided a useful framework to guide discussion with my medical team when discussing...
Hawk56 profile image

Moderation team

Bethishere profile image
BethishereAdministrator
Number6 profile image
Number6Administrator
Darryl profile image
DarrylPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.